The issues identified below are priority areas of prescribing, where there is unwarranted variation within Health Boards and where accurate prescribing data can be provided. Ensuring asthma medicines are reviewed and optimised regularly will reduce this unwarranted variation.

The indicators below help to highlight some higher risk groups who may benefit from prioritisation of review, focusing on patient safety and quality prescribing. Consideration should be given to prioritisation of these groups to optimise care.

The indicators focus on ensuring quality prescribing and any of the recommendations made follow national clinical guidance.6